This HTML5 document contains 138 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n9http://dx.doi.org/10.2337/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37106527
rdf:type
wikibase:Item
schema:description
مقالة علمية نشرت في 05 أبريل 2013 bilimsel makale wissenschaftlicher Artikel наукова стаття, опублікована у квітні 2013 artigo científico article scientifique scientific article published on 05 April 2013 vedecký článok articolo scientifico научни чланак article científic vetenskaplig artikel vědecký článek artículu científicu espublizáu en 2013 videnskabelig artikel wetenschappelijk artikel
p:P577
wds:Q37106527-8ADCEDD0-DD68-4AE0-8A01-B8B9499DC353
wdt:P577
2013-04-05T00:00:00Z
p:P407
wds:Q37106527-067108AE-8A37-468C-8A10-B0BBE6601666
wdt:P407
wd:Q1860
p:P2860
wds:Q37106527-7B48E15D-2FD2-4461-BCFF-DA598EA8EB27 wds:Q37106527-84DAFB46-88DF-4BAE-8539-2B785B48D416 wds:Q37106527-87306356-E1FE-46F4-B56C-549E1E128A43 wds:Q37106527-8E373A27-EEF5-4093-8E7D-4623100D6649 wds:Q37106527-90E0CCBE-6084-465E-916F-FE35AE3F325D wds:Q37106527-B5269BD2-45F9-4DC2-9FEB-5FE4A9AF82D1 wds:Q37106527-B75FCDA2-0C7A-4555-9FC8-D4AF8D4A198B wds:Q37106527-BA5ACFBD-0EAF-44E5-95D3-31A6DA063988 wds:Q37106527-BA864473-714A-466F-92C5-96D346C98C71 wds:Q37106527-BC16C98B-B72C-493F-9601-14DAF9D0BAEE wds:Q37106527-C04FFC13-4ADB-46F2-9794-14463BEA315E wds:Q37106527-C3912625-734F-48F3-BFCE-D5386959D062 wds:Q37106527-CA09A157-DE46-4429-98FE-0D2F877B73C1 wds:Q37106527-CC1B4420-6158-410D-909F-B7C8A2D5C5F4 wds:Q37106527-E01290ED-7AF2-4797-9E7E-35645067D8EA wds:Q37106527-EAFBD8FC-0CBB-48B9-BFC9-8F73C98706F1 wds:Q37106527-00FEFF5C-7746-46EB-B627-4DAA4457A355 wds:Q37106527-FD796DEF-0BD1-4FED-88FE-6353AC42ABE8 wds:Q37106527-0B0E52A8-BD6E-46C4-ACA5-13962F038623 wds:Q37106527-0E5C7A0D-151C-470E-BBBC-F4B3DCFF8021 wds:Q37106527-0FED8DF8-19E3-470E-8AF0-E4F4D8751361 wds:Q37106527-3D77AAF3-8814-4E94-AA6D-5C2EC08634AC wds:Q37106527-3D7C46BE-2AA1-4846-BCCC-14D72891F9F4 wds:Q37106527-3F6B904F-5BE1-420E-98CB-6B194246DD24 wds:Q37106527-4669F3CB-95F0-403F-BB83-DD0247182647 wds:Q37106527-491A2CB9-ECDE-4EF7-8805-A21717835826 wds:Q37106527-4CB10068-671F-4DA1-971F-FDA5CA7A5DD9 wds:Q37106527-5A3DA907-7A86-4490-8999-C692AA52C672 wds:Q37106527-6B55D015-7A8A-43F5-A2A4-AECFA2BE5322
wdt:P2860
wd:Q42944430 wd:Q51478110 wd:Q51468797 wd:Q46458866 wd:Q28732080 wd:Q24563606 wd:Q33901958 wd:Q51359456 wd:Q51362851 wd:Q36578983 wd:Q34227891 wd:Q37706255 wd:Q51372081 wd:Q46458837 wd:Q34646948 wd:Q45926087 wd:Q45124469 wd:Q43978130 wd:Q22241288 wd:Q37703184 wd:Q42153763 wd:Q37439364 wd:Q37348811 wd:Q83764954 wd:Q47305403 wd:Q36439877 wd:Q79866587 wd:Q46114555 wd:Q42873604
p:P2093
wds:Q37106527-1278C1E5-56A3-43E8-8B14-90FAB647AC12 wds:Q37106527-0FF7A691-B78C-49F5-AF98-957A29E516E3 wds:Q37106527-07D7CBAE-423A-49E0-B1DE-8996DE3CA76E wds:Q37106527-B3074FA0-7542-49E9-895E-1DC9926F4255 wds:Q37106527-B3E26C1B-2483-43B0-AD98-07E71D5CFD19 wds:Q37106527-93F3CDE1-AF91-4B41-B178-A4AFD4E83EA7 wds:Q37106527-5690C30D-ACCD-48C1-B5A3-E8F0207A2600 wds:Q37106527-748B8087-391D-401B-8EED-D4691BB7713C
wdt:P2093
Min Fu William Canovatchel Jacqueline Yee Michael Guarisco Masato Kawaguchi Guntram Schernthaner Gary Meininger Jorge L Gross
rdfs:label
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
skos:prefLabel
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
schema:name
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
p:P50
wds:Q37106527-021AB9D6-F8AF-4637-80BB-7573C6E3FA05
wdt:P50
wd:Q60996888
p:P1476
wds:Q37106527-5B8BCB63-52C4-4FEC-871B-912D3CB2827B
wdt:P1476
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
p:P304
wds:Q37106527-41C30FC7-B21A-47F9-A819-D731632C70A1
wdt:P304
2508-2515
p:P31
wds:Q37106527-33240449-F6E0-4A27-8278-F3007D6EA953
wdt:P31
wd:Q13442814
p:P921
wds:Q37106527-4CA0428C-B62A-4AC5-827E-A90555FDE1AD wds:Q37106527-F0324193-8814-48EA-A155-E63B51A9B0CE wds:Q37106527-8ACC6DA7-9325-44D6-A28B-74614CACE103 wds:Q37106527-7B7FA5C0-BE17-4AAD-A0A9-8CBB4C06C791 wds:Q37106527-71B017C7-61C9-43F3-BB71-3B83260F1D90
wdt:P921
wd:Q3025883 wd:Q181600 wd:Q47495780 wd:Q19484 wd:Q5030940
p:P698
wds:Q37106527-C0FA1F1A-967A-4B3F-9391-9F38C626463D
wdtn:P698
n12:23564919
wdt:P698
23564919
p:P1433
wds:Q37106527-35E32982-2D3D-458E-B4B6-0828E733ABE3
wdt:P1433
wd:Q5270111
p:P433
wds:Q37106527-C50FF852-728C-4537-A011-0BD57281A4E0
p:P478
wds:Q37106527-5374A325-FB0B-4186-A76B-F7C80EEB77DA
wdt:P433
9
wdt:P478
36
p:P356
wds:Q37106527-677E88E2-6C14-4BAD-9033-D4F587A01B96
wdtn:P356
n9:DC12-2491
wdt:P356
10.2337/DC12-2491
p:P5875
wds:Q37106527-528A211F-15B8-438C-8CC6-555F64CB8515
wdt:P5875
236129529
p:P932
wds:Q37106527-6F8C8681-9009-4B8E-8553-78BAE61FEEC5
wdt:P932
3747923